Goodcap is an early stage life sciences company developing therapies to improve brain and mental health by combatting neuroinflammation. GoodCap’s lead drug candidate, GCAP001, combines two active molecules that work synergistically to reduce key inflammatory biomarkers and symptoms associated with PTSD, depression and other mental health disorders.

Pattern is a biotechnology company focused developing therapies that mobilize innate immunity to address immune failures underpinning a wide range of infectious diseases and cancers. Pattern’s lead asset, PPI-100, is a TLR4 agonist that activates dendritic cells (DCs) and macrophages, causing them to become killer DCs and killer macrophages, which in turn activate NK cells. PPI-100 is first being developed in the perioperative setting to address the 40% relapse rate in cancer patients 5 years after surgical resection.

Mesa is a San Diego-based healthcare test and data company that developed the Accula System, an affordable, easy-to-use, point-of-care PCR-based testing platform for infectious disease diagnosis. The platform enables rapid, highly accurate testing at physician offices, pharmacies and other settings, providing results in 30 minutes. Beyond COVID-19 testing, Mesa Biotech's existing platform includes tests for flu, respiratory syncytial virus (RSV), and Strep A.In February 2021, Thermo Fisher acquired Mesa for $550 million: https://www.fiercebiotech.com/medtech/thermo-fisher-nets-handheld-covid-19-test-maker-mesa-biotech-550m-deal

Sublimity was a Dublin-based clinical stage pharmaceutical company developing therapies for gastrointestinal and immunological diseases. Sublimity’s lead asset, ST-0529, was in Phase 2b studies for the treatment of moderate-to-severe ulcerative colitis.

Cynapsus was a specialty CNS pharmaceutical company that developed a fast-acting, sublingual thin film for the on-demand turning ON of debilitating OFF episodes associated with Parkinson's disease. Responsible for Cynapsus' public company operations on TSX and NASDAQ, including regulatory, compliance, legal, finance, accounting and administrative functions. In capacity as CFO, supervised the controller, treasury, tax, audit, insurance, information technology and security, investor relations and facilities functions. Also worked closely with the Board of Directors, Audit Committee, Corporate Governance, Nominating and Compensation Committee, and Special Committee of the Board. While acting as CFO, Cynapsus raised approximately $170 million primarily via private placements and public offerings, including a $90 million re-US IPO and NASDAQ listing. Cynapsus also received two grants from The Michael J. Fox Foundation for Parkinson's Research, the world’s largest non-profit funder of Parkinson’s research.In October 2016, Cynapsus was acquired for $841 million (all cash) by Sunovion Pharmaceuticals, a wholly owned subsidiary of Sumitomo Dainippon Pharma: https://www.businesswire.com/news/home/20160831006494/en/Sunovion-Pharmaceuticals-Acquire-Cynapsus-Therapeutics